Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 47 of 143 for:    NIFEDIPINE

Treating Postictal Symptoms Using Ibuprofen and Nifedipine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03949478
Recruitment Status : Not yet recruiting
First Posted : May 14, 2019
Last Update Posted : May 14, 2019
Sponsor:
Information provided by (Responsible Party):
University of Calgary

Brief Summary:
This study will evaluate the effect of ibuprofen or nifedipine on post-seizure hypoperfusion and neurological deficits in patients with epilepsy. One group will receive ibuprofen, another will receive nifedipine, and anther placebo.

Condition or disease Intervention/treatment Phase
Epilepsy Epilepsies, Partial Drug: Ibuprofen Drug: Nifedipine Drug: Placebo Phase 2

Detailed Description:

Immediately following seizures, brain blood flow is significantly reduced for approximately one hour and is located to the brain area where the seizure originated. This may contribute to symptoms that patients experience immediately following seizures and in between seizures.

Animal studies have shown that that giving anti-inflammatory drugs (e.g., ibuprofen) and blood pressure medications (e.g., nifedipine) prevents the hypoperfusion and behavioural impairments seen in animals immediately following seizures. Thus, two classes of inexpensive and well-tolerated drugs - already in clinical use - have been identified that can be tested in humans to prevent the serious consequences that follow seizures.

The investigators will study 90 subjects admitted to hospital for epilepsy investigations. The investigators will randomly divide the patients into three treatment groups (30 patients each). Patients will receive either placebo, ibuprofen, or nifedipine while in hospital. The effect of each of these treatments on the severity of hypoperfusion and neurological deficits that follows seizures will then be assessed.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: We will study 90 subjects admitted to hospital for epilepsy investigations. We will randomly divide the patients into three treatment groups (30 patients each). They will receive either placebo, ibuprofen, or nifedipine while in hospital. We will then determine the effect of each of these treatments on the severity of hypoperfusion and neurological deficits that follows their seizures.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: The UofC Clinical Research Unit, which has no contact with patients or clinicians, will prepare the concealed randomization schedule and the randomization tool. Our research pharmacy will prepare three identical tablets to be given to each subject. The participant, care provider, investigators, and outcomes assessors will be blinded to treatment
Primary Purpose: Treatment
Official Title: An Initial Clinical Study to Treat Postictal Symptoms
Estimated Study Start Date : June 2019
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2022


Arm Intervention/treatment
Placebo Comparator: Placebo
Patients will receive placebo for at least five days prior to the first blood flow study. They will continue to receive placebo until the baseline study is obtained after the postictal study has been completed.
Drug: Placebo
Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.

Experimental: Ibuprofen
Patients will receive ibuprofen 400 mg by mouth three times a day (po tid) for at least five days prior to the first blood flow study. They will continue to receive ibuprofen until the baseline study is obtained after the postictal study has been completed.
Drug: Ibuprofen
Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
Other Name: Advil headache & migraine extra strength; DIN 02467658

Experimental: Nifedipine
Patients will receive nifedipine 10 mg po tid for 2 days, then 20 mg po tid, thereafter for at least five days prior to the first blood flow study. They will continue to receive nifedipine until the baseline study is obtained after the postictal study has been completed.
Drug: Nifedipine
Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
Other Names:
  • Adalat XL 20 mg, DIN 02237618
  • Adalat XL 30 mg, DIN 02155907




Primary Outcome Measures :
  1. Postictal blood flow [ Time Frame: 5 - 40 days ]
    Change in cerebral blood flow following seizures, relative to baseline. It will be measured by CT perfusion or ASL MRI.


Secondary Outcome Measures :
  1. Neuropsychological performance - Picture Sequence Memory Test [ Time Frame: 5 - 40 days ]

    For all Cognition Domain tests, three standardized scores are provided:

    • An uncorrected score comparing the test-taker to all individuals in the NIH Toolbox normative sample (mean = 100, SD = 15);
    • An age-corrected score that compares the test-taker to NIH Toolbox age-matched individuals (mean = 100, standard deviation = 15); and
    • A fully-corrected T-score that adjusts for key demographic variables including age, sex, race/ethnicity, and educational attainment (mean = 50, standard deviation = 10).

    Measure = Picture sequence memory Construct = Episodic memory

    Scale ranges:

    • uncorrected score (mean = 100, SD = 15).
    • age-corrected score (mean = 100, SD = 15).
    • fully-corrected T-score (mean = 50, SD = 10). For this test, a greater standardized score indicates better episodic memory.

  2. Neuropsychological performance - Flanker Inhibitory Control and Attention Test [ Time Frame: 5 - 40 days ]

    Measure = Flanker Inhibitory Control and Attention Test Construct = Executive Function & Attention

    Scale ranges:

    • uncorrected score (mean = 100, standard deviation = 15). Higher score is better
    • age-corrected score (mean = 100, standard deviation = 15). Higher score is better.
    • fully-corrected T-score (mean = 50, standard deviation = 10). Higher score is better.

    For this test, a higher raw or standardized score indicates greater inhibitory control and attention.


  3. Neuropsychological performance - List Sorting Working Memory Test [ Time Frame: 5 - 40 days ]

    Measure = List Sorting Working Memory Test Construct = Working Memory

    Scale ranges:

    • uncorrected score (mean = 100, standard deviation = 15). Higher score is better
    • age-corrected score (mean = 100, standard deviation = 15). Higher score is better.
    • fully-corrected T-score (mean = 50, standard deviation = 10). Higher score is better.

    For this test, a greater raw or standardized score indicates better episodic memory.


  4. Neuropsychological performance - Picture Vocabulary Test [ Time Frame: 5 - 40 days ]

    Measure = Picture Vocabulary Test Construct = Language

    Scale ranges:

    • uncorrected score (mean = 100, standard deviation = 15). Higher score is better
    • age-corrected score (mean = 100, standard deviation = 15). Higher score is better.
    • fully-corrected T-score (mean = 50, standard deviation = 10). Higher score is better.

    For this test, a higher standardized score indicates greater general vocabulary knowledge.


  5. Neuropsychological performance- Oral Reading Recognition Test [ Time Frame: 5 - 40 days ]

    Measure = Oral Reading Recognition Test Construct = Language

    Scale ranges:

    • uncorrected score (mean = 100, standard deviation = 15). Higher score is better
    • age-corrected score (mean = 100, standard deviation = 15). Higher score is better.
    • fully-corrected T-score (mean = 50, standard deviation = 10). Higher score is better.

    For this test, a higher standardized score indicates a greater ability to read aloud.


  6. Neuropsychological performance - Dimensional Change Card Sort Test [ Time Frame: 5 - 40 days ]

    Measure = Dimensional Change Card Sort Test Construct = Executive function

    Scale ranges:

    • uncorrected score (mean = 100, standard deviation = 15). Higher score is better
    • age-corrected score (mean = 100, standard deviation = 15). Higher score is better.
    • fully-corrected T-score (mean = 50, standard deviation = 10). Higher score is better.

    For this test, a greater raw or standardized score indicates greater cognitive flexibility.


  7. Neuropsychological performance - Pattern Comparison Processing Speed Test [ Time Frame: 5 - 40 days ]

    Measure = Pattern Comparison Processing Speed Test Construct = Processing Speed

    Scale ranges:

    • uncorrected score (mean = 100, standard deviation = 15). Higher score is better
    • age-corrected score (mean = 100, standard deviation = 15). Higher score is better.
    • fully-corrected T-score (mean = 50, standard deviation = 10). Higher score is better.

    For this test, a greater raw or standardized score indicates faster processing speed.


  8. Psychological well-being [ Time Frame: 5 - 40 days ]

    The Psychological Well-Being measure assesses a subjective and experiential aspect of pleasure and positive affect, as well as fulfillment and purpose. Psychological Well-being composite scores are generated as the weighted average of the uncorrected standardized score (T scores; mean = 50, SD = 10) obtained from each subdomain:

    Positive Affect Construct = This portion assesses positive affect, or feelings of a pleasurable engagement with the environment, using a positive affect survey.

    Higher scores = more positive affect.

    Life Satisfaction Construct = This portion assesses how the participant evaluates their life, in terms of whether they like it or not, using a life satisfaction survey.

    Higher scores = greater life satisfaction.

    Meaning and Purpose Construct = This portion evaluates the degree to which the participant feels their life matters or makes sense.

    Higher scores = greater sense of meaning and purpose.


  9. Social Relationships [ Time Frame: 5 - 40 days ]

    The Social Relationships measure assesses the participants social network structure, extent, and quality. Composite social satisfaction composite scores are generated as the weighted average of the T-scores (mean = 50, SD = 10) from the subdomains, with loneliness and perceived rejection reverse-coded.

    Perceived Social Support Construct = This portion evaluates the degree to which the participant feels their life matters or makes sense.

    Higher scores = greater sense of meaning and purpose.

    Companionship Construct = This portion assesses self-reported perceptions of the participant has companions to interact with and perceptions of being alone or lonely.

    Higher scores = higher perceived friendship or more loneliness.

    Social Distress Construct = This portion evaluates the degree to which the participant feels their life matters or makes sense.

    Higher scores = greater perceived hostility and rejection.


  10. Stress and Self-Efficacy Relationships [ Time Frame: 5 - 40 days ]

    The Stress and Self-Efficacy measure assesses the individual's perception of life events and their relationships as well as their perceived coping skills. Stress and self-efficacy composite scores are generated as the weighted average of the T-scores (mean = 50, SD = 10) from the subdomains

    Perceived Stress Construct = This portion evaluates the participants perceived stress. Higher scores = greater perceived stress.

    Self-Efficacy Construct = This portion assesses self-efficacy, or the participants belief in their capacity to manage and have control over events.

    Higher scores = more general self-efficacy.


  11. Negative affect [ Time Frame: 5 - 40 days ]

    composite scores are generated as the weighted average of the T-scores from the subdomains. Negative affect includes the following subdomains:

    Anger Construct = This portion assesses attitudes of hostility and cynicism. Higher scores = higher levels of anger.

    Fear Construct = This portion assesses the participants perception of threat and autonomic arousal associated with fear.

    Higher scores = higher levels of fear.

    Sadness Construct = This portion assesses the participants feelings of sadness, or their low levels of positive affect or low mood.

    Higher scores = more sadness.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age > 16 yrs, frequent seizures (>1 per week) and cognitive ability sufficient to complete neuropsychological testing.

Exclusion Criteria:

  • multiple seizure onset zones, contraindications to CT or MR imaging, any contraindication to ibuprofen or nifedipine, as well as current or recent (< 2 months) exposure COX-2 inhibitor or calcium channel blocker.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03949478


Contacts
Layout table for location contacts
Contact: Paolo Federico, MD, PhD =1.403.944.4091 pfederic@ucalgary.ca

Locations
Layout table for location information
Canada, Alberta
Foothills Medical Centre Not yet recruiting
Calgary, Alberta, Canada, T2N T29
Contact: Paolo Federico, MD, PhD    +1.403.944.4091    pfederic@ucalgary.ca   
Sponsors and Collaborators
University of Calgary
Investigators
Layout table for investigator information
Principal Investigator: Paolo Federico, MD, PhD University of Calgary

Layout table for additonal information
Responsible Party: University of Calgary
ClinicalTrials.gov Identifier: NCT03949478     History of Changes
Other Study ID Numbers: TPS-1.0
First Posted: May 14, 2019    Key Record Dates
Last Update Posted: May 14, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by University of Calgary:
Postictal
Blood flow
Additional relevant MeSH terms:
Layout table for MeSH terms
Nifedipine
Epilepsy
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Ibuprofen
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents